NCT01809301View on ClinicalTrials.gov

Comparison of TRIA-662 500 mg and Niaspan 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Healthy
Interventions
DRUG

Niaspan

DRUG

TRIA-662

Trial Locations (1)

M9L 3A2

Bio Pharma Services Inc. (BPSI), Toronto

Sponsors
All Listed Sponsors
collaborator

PPD Development, LP

INDUSTRY

collaborator

Pharmena North America

INDUSTRY

lead

Cortria Corporation

INDUSTRY

NCT01809301 - Comparison of TRIA-662 500 mg and Niaspan 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions | Biotech Hunter | Biotech Hunter